about
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, inject...
Read More
50.03
-3.91
(-7.25%)
64.2M
XNYS Volume
High volume+loss today
XNYS 30 Jul, 2025 4:18 PM (EDT)
CEO Appointment
Novo Nordisk names insider Maziar Doustdar as CEO after Wegovy sales slump in Q2
See details
Medium Financial Strength
Mid Valuation
Technically Bearish
Slowing Down Stock
These stocks score good in Quality and also have medium range financials. However, a bad technical scoring and bearish aspects decrease the investor's interest over time.
View Similar
Embed DVM
Novo Nordisk - ADR Live Price Chart
Switch to TradingView
Loading Fundamental data..
Loading data..